Medindia

X

Anti-Clotting Drug Apixaban Receives NICE Approval

by Kathy Jones on  November 26, 2011 at 5:36 PM Drug News   - G J E 4
British drug regulator National Institute for Health and Clinical Excellence (NICE) has approved the use of the anti-clotting drug manufactured by Pfizer and Bristol-Meyers, apixaban, in preventing blood clots post hip and knee surgery.
 Anti-Clotting Drug Apixaban Receives NICE Approval
Anti-Clotting Drug Apixaban Receives NICE Approval
Advertisement

NICE said that apixaban, which is being marketed under the brand name Eliquis, was a cost effective and clinically effective option in treating blood clots.

Advertisement
The treatment for knee replacement patients will last for 12 days and will cost around £41.16 while it will last for 34 days for hip replacement patients and will cost £116.62.




Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All